In Brief: Digene
This article was originally published in The Gray Sheet
Executive Summary
Digene: Submits premarket approval application supplement to FDA for its Hybrid Capture II human papillomavirus DNA test. The test is a next generation to the firm's Hybrid Capture test, permitting "simultaneous testing of multiple samples from a single 96-well microtiter plate." When used in conjunction with Pap smear testing, the Hybrid Capture II test can detect 95-100% of high grade lesions and "virtually all instances of cervical cancer," Digene claims. The Beltsville, Maryland firm plans to develop the test's format to allow simultaneous testing of HPV, chlamydia and gonorrhea from a single patient specimen, and it expects to submit 510(k)s to FDA for tests for those diseases in 1998...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.